EORTC abstracts selected at EBCC-12 Virtual Congress
28 Sep 2020
3 EORTC abstracts were selected for the 12th European Breast Cancer Conference (EBCC-12) that will take place virtually on 2-3 October 2020.
Plenary Session
Keynote Lecture, Best and Late Breaking Abstract Presentations
Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial
- Presentation number: ORAL-007
- Date: 2 October 2020, 13:50-14:00
- Speaker: Otto Metzger (USA)
Proffered Papers Session
Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer
- Presentation number: ORAL-021
- Date: 3 October 2020, 13:00-13:10
- Speaker: Emiel Rutgers (The Netherlands)
Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers
- Presentation number: ORAL-011
- Date: 3 October 2020, 12:50-13:00
- Speaker: Josephine Lopes Cardozo (The Netherlands)
- MINDACT: 70-gene signature test as guidance for breast cancer treatment – video interview of Josephine Lopes Cardoso (source: ecancer)
EBCC-12 is a breast cancer conference where the very latest practice-changing research is presented. It aims to provide a unique multidisciplinary setting for all professionals with a common interest in breast cancer to discuss, debate, inform and educate themselves about this evolving disease.
To view the full two day programme, visit the EBCC-12 searchable programme.
Registration for the virtual event is still open. For further information click here.
Related News
EORTC strategic meeting with Middle Eastern Ambassadors
26 Sep 2023
EORTC Quality of Life Group projects to be presented at ISOQOL 2023
22 Sep 2023
Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study
17 Jul 2023
“Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference
30 Jun 2023
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
16 Jun 2023
Joint Statement: health organisations define EHDS’ opt out required for life saving research
9 Jun 2023
Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award
7 Jun 2023
Full validation of the EORTC CAT Core
6 Jun 2023
SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials
1 Jun 2023
Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types
30 May 2023